Trials / Terminated
TerminatedNCT03344003
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq - A Canadian Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 14 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Uncontrolled, multi-centre, non-interventional study with a prospective and a retrospective cohort, to evaluate the efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in severe and moderate haemophilia A patients with inhibitors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Wilate or Nuwiq | Wilate or Nuwiq administered via intravenous injection |
Timeline
- Start date
- 2018-06-28
- Primary completion
- 2020-11-20
- Completion
- 2020-11-20
- First posted
- 2017-11-17
- Last updated
- 2024-08-09
- Results posted
- 2024-08-09
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03344003. Inclusion in this directory is not an endorsement.